Algene Holding SE, a subsidiary of DN Group AG (ISIN: DE000A3DW408), has reached a significant milestone with the first harvest of high-purity microalgae, yielding 4,500 litres. This achievement marks the start of series production following successful up-scaling, with the microalgae intended for quality-critical applications in cosmetics, food, and potentially pharmaceuticals.
The Algene platform, developed in collaboration with the Technical University of Munich, is now transitioning to series production. The company has already engaged in extensive discussions with well-known cosmetics firms, and the first delivery to a leading German cosmetics manufacturer is imminent. This initial shipment will primarily be used for laboratory tests and validation of active ingredients.
The market for microalgae is experiencing dynamic growth, with the European Commission projecting a market size of around 9 billion euros by 2030 within Europe alone. Algae are recognized as a key component of the bioeconomy, and Algene is positioning itself as an industrial platform for controlled microalgae production, targeting sectors such as nutrition, cosmetics, life sciences, and aquaculture.
Ole Nixdorff, CEO of DN Group, commented: "For Algene, the start of series production is an important milestone. The market for microalgae is growing rapidly and offers enormous potential. The high level of interest underlines the high quality of the Algene material and the good market acceptance. As a shareholder in Algene, DN Group participates in this future market."
DN Group AG invests in impact companies with high growth opportunities in future industries such as AI, mobility, circular economy, food, health, and energy, supporting them in successful IPOs. The company is one of the leading providers of IPO and capital market transaction advice, connecting fast-growing ESG companies with international institutional investors.
For more information, visit www.dn-ag.com or view the original release on www.newmediawire.com.
